1. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
- Author
-
Lee LJ, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, Jackson JA, and Davidson JA
- Subjects
- Adult, Diabetes Complications economics, Diabetes Complications epidemiology, Diabetes Mellitus, Type 2 economics, Drug Therapy economics, Female, Humans, Hypoglycemia chemically induced, Hypoglycemia economics, Hypoglycemia epidemiology, Hypoglycemic Agents economics, Hypoglycemic Agents therapeutic use, Insulin adverse effects, Insulin economics, Insulin therapeutic use, Insulin Glargine, Insulin, Isophane adverse effects, Insulin, Isophane therapeutic use, Insulin, Long-Acting, Male, Middle Aged, Patient Selection, Probability, Propensity Score, Retrospective Studies, United States, Diabetes Mellitus, Type 2 drug therapy, Insulin analogs & derivatives, Insulin, Isophane economics
- Abstract
Aims: To compare total costs and risk of hypoglycemia in patients with type 2 diabetes (T2D) initiated on NPH insulin versus glargine in a real-world setting., Methods: This study used claims data (10/2001 to 06/2005) from a privately insured U.S. population of adult T2D patients who were initiated on NPH or glargine following a 6-month insulin-free period. A sample of 1698 glargine-treated and 400 NPH-treated patients met the inclusion criteria. Total and diabetes-related costs (inflation-adjusted to 2006) were calculated for 6-month pre- and post-index periods and compared between 400 patient pairs matched by a propensity score method., Results: In the post-index 6-month period, glargine patients incurred higher diabetes-related drug costs than NPH patients ($785 versus $632, p<0.0001) but there were no significant differences in diabetes-related medical or total costs, or all other total cost categories. Compared to the pre-index period, glargine patient costs declined by $2420 (p=0.058) whereas NPH patient costs declined by $4200 (p=0.046), with no statistically significant group differences (p=0.469). Among patients with hypoglycemia-related claims (0.75% in both groups), mean hypoglycemia-related costs were $85 and $202 for NPH and glargine patients, respectively (p=0.564)., Conclusion: Initiation of either NPH or glargine was associated with major cost reductions and infrequent hypoglycemia-related claims., (Copyright 2009 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF